13 active
/
53 total (since 2015)
3
Phase 1 Active
12 total
8
Phase 2 Active
17 total
4
Phase 3 Active
25 total
1
Phase 4 Active
4 total
Top Sponsors (Industry)
Sorted by active Active Done Failed
Changchun GeneScience Pharmaceutical Co., Ltd. 4 5 0
Lumos Pharma 4 2 0
Novo Nordisk 0 8 0
Ascendis Pharma Endocrinology Division A/S 0 4 0
Versartis Inc. 0 1 3
OPKO Health, Inc. 0 3 0
NCT06948214 RECRUITING
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
Lumos Pharma n=150
NCT04867317 RECRUITING
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
VA Office of Research and Development n=172
NCT07126288 NOT YET RECRUITING
Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency
Shenzhen Kexing Pharmaceutical Co., Ltd. n=268
NCT07129759 NOT YET RECRUITING
Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency
Lumos Pharma n=150
NCT05171855 COMPLETED
A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
Ascendis Pharma Endocrinology Division A/S n=220
NCT03811535 COMPLETED
A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)
Novo Nordisk A/S n=200
NCT04970654 COMPLETED
A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.
Novo Nordisk A/S n=110
NCT02968004 COMPLETED
Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
OPKO Health, Inc. n=224
NCT04615273 COMPLETED
A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
Ascendis Pharma Endocrinology Division A/S n=264
NCT04786873 COMPLETED
A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is
AEterna Zentaris n=101
NCT03344458 COMPLETED
A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial
Ascendis Pharma A/S n=298
NCT04633057 COMPLETED
A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone Deficiency
TJ Biopharma Co., Ltd. n=168
NCT04513171 COMPLETED
Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children
Xiamen Amoytop Biotech Co., Ltd. n=434
NCT03223025 COMPLETED
Comparing Efficacy and Safety of CinnaGen Biosimilar Growth Hormone (CinnaTropin®) Versus Nordilet in Children With Idiopathic Growth Hormone Deficiency
Cinnagen n=30
NCT02413138 TERMINATED
Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)
Versartis Inc. n=41
NCT02410343 TERMINATED
Study of TV-1106 in Growth Hormone-Deficient Adults
Teva Branded Pharmaceutical Products R&D, Inc. n=14
NCT02781727 COMPLETED
A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
Ascendis Pharma Endocrinology Division A/S n=162
NCT03305016 COMPLETED
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
Ascendis Pharma Endocrinology Division A/S n=146
NCT02410356 TERMINATED
Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)
Teva Branded Pharmaceutical Products R&D, Inc. n=34
NCT03831880 COMPLETED
Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD
Pfizer n=87
NCT03874013 COMPLETED
Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency
OPKO Health, Inc. n=44
NCT03075644 COMPLETED
A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency
Novo Nordisk A/S n=62
NCT02382939 COMPLETED
A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency
Novo Nordisk A/S n=92
NCT02558829 COMPLETED
Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency
AEterna Zentaris n=157
NCT03145831 TERMINATED
A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency
Versartis Inc. n=21
Data: ClinicalTrials.gov